Study for chronic lymphocytic leukemia after venetoclax failure
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of chronic lymphocytic leukemia (CLL).
- Your CLL must have come back or progressed during or after venetoclax treatment.
- You must have tumor/blood samples available for the study team to analyze.
- You must be able to consent (agree) to participate, if needed.
- You must be covered by the French Social Security system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests a combination of three drugs—roginolisib, obinutuzumab, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to previous treatment. The goal is to see if this combination can help control the disease.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This study looks at how venetoclax affects the area around CLL cells in the lymph nodes. You will have a lymph node biopsy to check these changes, which might help doctors understand how the treatment works.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.